



S0040-4039(96)00117-7


Taxoids: 11,12-Dihydro-4-deacetyl docetaxel

Raphaële Marder, Laurent Bricard, Joëlle Dubois, Daniel Guénard, Françoise Guéritte-Voegelein*

Institut de Chimie des Substances Naturelles - CNRS 91198 Gif sur Yvette Cedex- France


Abstract : 11,12-dihydro-4-deacetyl docetaxel was prepared from 10-deacetyl baccatin III via its reduced derivative at C11, C12. The title compound is not active on microtubules disassembly.

Taxoids are a series of new anticancer drugs¹ which inhibit cell growth by interacting with microtubules.² Among these substances, Taxol® (paclitaxel) **1**³ and Taxotere® (docetaxel) **2**⁴ are clinically active against ovarian, breast and lung cancers. In order to obtain new compounds with improved biological activity and to study the structure-activity relationships in this series, a number of structural modifications have been performed on paclitaxel and docetaxel. These modifications include mainly the ester groups at C-2, C-4, and C-13, the oxetane D ring as well as the oxygenated functions at C-7, C-9 and C-10⁵. On the contrary, only few analogues modified at the C-11, C-12 positions have been prepared^{5c} and, to date, no information is available on the direct influence of the A-ring double bond on the antitubulin activity.




We have previously described the synthesis of 11,12-dihydro-10-deacetyl baccatin III **4** and of its 7-triethylsilyl derivative **5** from 10-deacetyl baccatin III **3**⁶, a renewable precursor isolated from the leaves of the European yew tree, *Taxus baccata*.⁷ Very recently, reduction of the C-11, C-12 double bond of baccatin III derivatives was also described by Appendino and coll.⁸ In order to obtain the 11,12-dihydro derivative of docetaxel, compound **5** was treated with 3 equivalents of the protected acid side chain **6**⁹ and a coupling agent (3 eq). Unfortunately, in our hands, no reaction occurred when we used the DCC or EDCI / DMAP procedure. On the other hand, treatment of **5** and acid side-chain **6** with NaHMDS / EDCI led to the 13-acetyl, 4-deacetyl derivative **7** (Scheme 1). The easy acyl transfer from C-4 to the hydroxyl group at C-13 can be explained by the very close proximity of these two groups as seen in the X-ray crystallography study of 11,12-dihydro-7-triethylsilyl-10-deacetyl baccatin III **5**.¹⁰

A solution to the C-13 acylation would be to introduce the proper acid side chain on the 4-deacetylated derivative **8** and then reacylate the C-4 hydroxyl group. Selective approaches to the removal of the C-4 acetyl group from baccatin III derivatives have been described in the literature.^{5e,11-16}



Scheme 1

Following one of these procedures,¹¹ the treatment of **5** with potassium *t*-butoxide afforded the desired 4-deacetylated derivative **8** (Scheme 1). Compound **8** was also obtained after reduction of the 13-oxo-4-deacetylated derivative **12**. This compound was prepared from 7-TES-10-deacetylbaccatin III **9** by reduction of the acetyl group with Super-hydride¹⁴ (compound **10**). Oxidation of **10** with PCC provided the 13-oxo derivative **11**. Finally, the double bond and the keto group were respectively reduced by zinc (compound **12**) and NaBH₄ to offer compound **8** (Scheme 2).




Scheme 2

The acid side chain **6**⁹ was then attached to **8**, using the DCC, DMAP procedure¹⁷ (compound **13**). Compound **13** underwent stepwise deprotection leading first to the desilylated derivative and then to 11,12-dihydro-4-deacetyldoctaxel **14**. Some epimerization at C-7 (compound **15**) also occurred under the

deprotection conditions (Scheme 3). 11,12-dihydro-4-deacetyldocetaxel **14** and its 7-epimer **15** exhibit mass, $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectra in agreement with the assigned structures.¹⁸

Many attempts have then been made to obtain 11,12-dihydrodocetaxel from the 4-deacetylated derivative **13**, but, to our disappointment, the hindered hydroxyl group at C-4 could not be acetylated, even under forcing conditions. For example, no reaction occurred when a solution of compound **13** in pyridine was treated with Ac_2O (20 eq), DMAP (20 eq) at 70°C . On the other hand, treatment with acetyl chloride under highly basic conditions (LiHMDS or NaHMDS) in THF led to the cleavage of the side-chain at C-13.



Scheme 3

Analogues **14** and **15** were evaluated *in vitro* on the disassembly process of microtubules into tubulin.¹⁹ 11,12-Dihydro-4-deacetyldocetaxel **14** and its 7-epimer **15** are inactive.²⁰ In comparison, in the microtubule disassembly assay, 4-deacetyldocetaxel²¹ possesses an IC_{50} of $4 \cdot 10^{-5}$ M. These results show that the A ring double bond is essential to the interaction of taxoids with microtubules.

Acknowledgments. The authors thank Prof. Pierre Potier for his constant interest of their work. We are also grateful to Dr. A. Commerçon for a gift of the acid side-chain and to Rhône-Poulenc Rorer S.A. for financial support.

References and notes

- Guénard, D.; Guéritte-Voegelein, F.; Lavelle, F. *Current Pharmaceutical Design* **1995**, *1*, 95-112.
- Schiff, P.B.; Fant, J.; Horwitz, S.B. *Nature*, **1979**, *277*, 665-667.
- Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. *J. Am. Chem. Soc.* **1971**, *93*, 2325-2327.
- Guéritte-Voegelein, F.; Guénard, D.; Lavelle, F.; LeGoff, M-T.; Mangatal, L.; Potier, P. *J. Med. Chem.* **1991**, *34*, 992-998.
- For recent overviews, see: a) Hepperle, M. and Georg, G.I. *Drugs of the Future*, **1994**, *19*, 573-584. b) Nicolaou, K.C.; Dai, W-M.; Guy, R.K. *Angew. Chem. Int. Ed. Engl.*, **1994**, *33*, 1583-1587. c) Guénard, D.; Guéritte-Voegelein, F.; Potier, P. *Acc. Chem. Res.*, **1993**, *26*, 160-167. d) Kingston, D.G.I.; Molinero, A.A.; Rimoldi, J.M. The Taxane Diterpenoids in *Progress in the Chemistry of Organic Natural Products*, Hertz, W., Kirby, G.W., Moore, R.E., Steglich, W. and Tamm, Ch., Ed.; Springer-Verlag, Wien, New York, 1993, Vol. 61, 1-206. e) Chen, S-H. and Farina, V. Paclitaxel (Taxol®) Chemistry and Structure-Activity Relationships in *The Chemistry and Pharmacology of Taxol and its Derivatives*, Farina, V. Ed.; Elsevier Science B.V. 1995, *22*, 165-253.
- Marder, R.; Dubois, J.; Guénard, D.; Guéritte-Voegelein, F.; Potier, P. *Tetrahedron*, **1995**, *51*, 1985-1994.
- Chauvière, G.; Guénard, D.; Picot, F.; Sénihl, V.; Potier, P. *C.R. Acad. Sci. Paris* **1981**, *293*, 501-503.
- Appendino, G.; Jakupovic, J.; Cravotto, G.; Enriù, R.; Varese, M.; Bombardelli, E. *Tetrahedron Lett.*, **1995**, *36*, 3233-3236.

9. Didier, E.; Fouque, E.; Taillepied, I.; Commerçon, A. *Tetrahedron Lett.*, **1994**, *35*, 2349-2352.
10. Chiaroni, A.; Riche, C.; Marder, R.; Dubois, J.; Guénard, D.; Guéritte-Voegelein., **1995**, *Acta. Cryst. C.*, *51*, 2050-2053.
11. Datta, A.; Jayasinghe, L. R.; Georg, G. I. *J.Org.Chem.*, **1994**, *59*, 4689-4690.
12. Neidigh, K.A.; Gharpure, M.M.; Rimoldi, J.M.; Kingston, D.G.I.; Jiang, Y.Q.; Hamel, E. *Tetrahedron Letters*, **1994**, *35*, 6839-6842.
13. Chen, S-H.; Kadow, J. F.; Farina, V.; Fairchild, C. R.; Johnston, K. A. *J.Org.Chem.*, **1994**, *59*, 6156-6158.
14. Guéritte-Voegelein, F.; Guénard, D.; Dubois, J.; Wahl, A.; Marder, R.; Müller, R.; Lund, M.; Bricard, L.; Potier, P. In *Taxane Anticancer Agents, Basic Science and Current Status*, Georg, G. I.; Chen, T. T.; Ojima, I.; Vyas, D. M., Ed.; ACS Symposium Series N°583; American Chemical Society: Washington, DC, **1995**, 189-202.
15. Chen, S-H.; Farina, V.; Wei, J-M.; Long, B.; Fairchild, C.; Mamber, S.W.; Kadow, J.F.; Vyas, D.; Doyle, T.W. *Biorg.Med.Chem.Lett.*, **1994**, *4*, 479-482.
16. Samaranyake, G.; Magri, N.; Jitrangsri, C.; Kingston, D.G.I., *J.Nat.Prod.*, **1993**, *56*, 884-898.
17. Denis, J-N.; Greene, A.; Guénard, D.; Guéritte-Voegelein, F.; Mangatal, L. and Potier, P. *J.Am.Chem.Soc.*, **1988**, *110*, 5917-5919.
18. Spectroscopic data of the title compound **14** and its 7-epimer **15**:
- 14**: IR (CHCl₃) 3495, 1718, 1706 cm⁻¹; FABMS m/z 790 [M+Na]; ¹H NMR (300 MHz, CDCl₃) δ 1.03 (3H, d, J = 8, C-18H₃), 1.16 (3H, s, C-16H₃), 1.26 (3H, s, C-17H₃), 1.42 (9H, s, Boc), 1.61 (3H, s, C-19H₃), 1.80 (1H, m, C-11H), 2.00 (2H, m, C-6H₂ et C-14H₂), 2.42 (1H, m, C-6H₂), 2.63 (1H, m, C-12H), 2.74 (1H, d, J = 16, C-14H₂), 3.72 (1H, d, J = 8, C-3H), 4.01 (1H, m, C-7H), 4.03 (1H, d, J = 8, C-20H₂), 4.50 (1H, d, J = 8, C-20H₂), 4.73 (1H, m, C-5H), 4.80 (1H, bs, C-2'H), 5.00 (1H, m, C-10H), 5.32 (1H, bs C-3'H), 5.41 (1H, m, C-13H), 5.72 (1H, d, J = 8, C-2H), 5.84 (1H, NH), 7.36 (5H, Ph), 7.47-7.61-8.00 (5H, OBz); ¹³C NMR (62 MHz, CDCl₃) δ 9.46 (C-18H₃), 15.80 (C-19H₃), 25.41 (C-16H₃), 28.42 (C-BocH₉), 32.15 (C-12H), 32.38 (C-17H₃), 34.81 (C-14H₂), 35.40 (C-6H₂), 40.47 (C-3H), 42.38 (C-15), 56.93 (C-8/C-3'H), 60.26 (C-11H), 69.70 (C-7H), 70.29 (C-10H), 73.82 (C-2H/C-13H), 75.22 (C-2'H), 75.55 (C-4 or C-1), 78.60 (C-1 or C-4), 80.89 (C-20H₂/Cq-Boc), 86.52 (C-5H), 126.95-128.07-128.85-138.63 (C-3'Ph), 129.06 (CH-*m* Bz), 129.36 (Cq Bz), 129.93 (CH-*o* Bz), 133.97 (CH-*p*Bz), 154.32 (CO Boc), 166.91 (COPh), 171.58 (C-1'), 208.05 (C-9).
- 15**: IR (CHCl₃) 3431, 1718, 1706 cm⁻¹; FABMS m/z 790 [M+Na]; ¹H NMR (400 MHz, CDCl₃) δ 1.03 (3H, d, J = 8, C-18H₃), 1.03 (3H, s, C-16H₃), 1.16 (3H, s, C-17H₃), 1.39 (9H, s, Boc), 1.67 (3H, s, C-19H₃), 1.79 (1H, dd, C-11H), 2.04 (1H, m, C-14H₂), 2.24 (1H, m, C-6H₂), 2.31 (1H, m, C-6H₂), 2.58 (1H, m, C-12H), 2.80 (1H, d, J = 16, C-14H₂), 3.81 (1H, m, C-7H), 3.87 (1H, d, J = 8, C-3H), 4.09 (1H, d, J = 8, C-20H₂), 4.59 (1H, d, J = 8, C-20H₂), 4.66 (1H, d, J = 5, C-2'H), 4.76 (1H, m, C-5H), 5.13 (1H, *s large*, C-3'H), 5.24 (1H, m, C-10H), 5.47(1H, m, C-13H), 5.51 (1H, NH), 5.72 (1H, d, J = 8, C-2H), 7.33 (5H, m, Ph), 7.45-7.55-8.06 (5H, OBz); ¹³C NMR (100 MHz, CDCl₃) δ 16.03 (C-18H₃), 17.28 (C-19H₃), 25.21 (C-16H₃), 28.48 (C-BocH₉), 32.40 (C-17H₃), 32.73 (C-12H), 35.21 (C-14H₂), 36.04 (C-6H₂), 38.80 (C-3H), 40.51 (C-15), 54.97 (C-8), 57.47 (C-3'H), 60.60 (C-11H), 74.20 (C-2H/C-13H), 75.32 (C-10H), 76.27 (C-2'H), 78.29 (C-7H), 78.62 (C-4 ou C-1), 79.87 (C-1 ou C-4), 81.38 (C-20H₂/Cq-Boc), 86.23 (C-5H), 127.37-128.34-128.84-137.66 (C-3'Ph), 129.0 (CH-*m* Bz), 130.08 (Cq Bz), 130.23 (CH-*o*Bz), 133.80 (CH-*p*Bz), 156.22 (CO Boc), 166.75 (COPh), 170.36 (C-1'), 209.41 (C-9).
19. Lataste, H.; Sénilh, V.; Wright, M.; Guénard, D.; Potier, P. *Proc.Natl.Acad.Sci.U.S.A.*, **1984**, *81*, 4090-4094.
20. The compounds considered as inactive on the disassembly process of microtubules into tubulin are those for which the IC₅₀ can not be reach. In the taxoid series, this corresponds to a concentration superior to about 10⁻⁴M.
21. This compound was obtained quantitatively from 7-SiEt₃-10-deacetylbaccatin III after selective reduction at C-4 with Super-hydride. Coupling of the 4-deacetyl derivative with the acid side chain **6** (76%) followed by acidic deprotection (41%) afforded 4-deacetydocetaxel. 4-Deacetyldocetaxel and 4-deacetylpaclitaxel have been synthesized by others teams (see for example Ref 11 and 12).

(Received in France 22 December 1995; accepted 8 January 1996)